Stockley Park

Gilead Sciences Europe Ltd. (International Headquarters)

2 Roundwood Avenue
South Building
Stockley Park
Uxbridge
Middlesex
UB11 1AF
View Google Map

Phone: 44 (0)208 587 2200
Fax: 44 (0)208 744 6773 

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.

 

Established in 2005, Gilead's International headquarters is located in Stockley Park in Uxbridge, west of London, England. The office provides centralized support for most of Gilead's operations outside the United States and Canada. The following functions are part of the team providing centralized support for our EU operations: General Management, Finance, Human Resources, Regulatory, Safety, Information Technology, Legal, Medical Affairs and EU Commercial Compliance.

Relationships with Charitable Organizations

Gilead provided support for the following charitable organizations in 2012, via unrestricted educational grants. The information is correct at the time of writing (March 2013). The information is subject to change and will be updated accordingly.

  • Grant Recipient
    Description of Activity
    Amount Funded
  • International Centre for Migration, Health and Development
    Guidelines on Viral Hepatitis and HIV in migrant populations
    36,500 CHF
  • Soa AIDS Nederland
    AIDS Action Europe Core Funding
    € 70,000
  • Fundacio Lluita Sida
    Interactive Resistance Information Project
    € 30,000
  • Q-Club
    Community Advocacy and Support for people living with HIV in Serbia
    € 10,800
  • World Hepatitis Alliance
    Core Funding 2012
    US$ 100,000
  • Fungal Research Trust
    Aspergillus Website 2012
    £20,000
  • European Liver Patients' Association
    Core Funding for education and training among people living with hepatitis
    € 100,000
  • European Patients Forum
    2012 Work Program
    € 15,000
  • Hepatitis B&C Public Policy Association - ASBL
    Core Funding
    € 50,000
  • HIVeurope
    Core Funding
    € 20,000
  • JUSTRI Limited
    Viral Hepatitis Clinic Guide and HIV Medical Students Course
    £24,250
  • European Aids Treatment Group
    Core Funding
    € 105,930
  • AIDS Fonds - SOA Netherlands
    Core Funding for the "HIV in Europe" organisation and its ongoing activities
    € 100,000
  • European Aids Treatment Group
    International Workshop on hepatitis C (Sitges V)
    € 10,000
  • European Aids Treatment Group
    3 European Community Advisory Board (ECAB) Meetings
    € 56,000
  • HIV i-Base
    Speaker Fees for Community Presentations at the World AIDS and Glasgow HIV-11 Conferences
    £2,000
  • European Aids Treatment Group
    Community Feedback Meeting Organisation at Retrovirus (CROI) and Glasgow HIV-11 Conferences
    € 4,940
  • Positively UK
    Photographic Support for Gilead Sciences Inc 2010 Annual Report
    £847
  • European Platform for Patients' Organisations, Science and Industry (EPPOSI)
    2011 Membership
    € 8,000
  • Sensoa
    Participation in Consultative Meeting on Treatment
    € 1,000
  • AIDES
    Participation in Consultative Meeting on Treatment
    € 450


This page is intended for visitors outside of the United States.